autologous bispecific bcma/cd19-targeted car-t cells gc012f vs cael-101
| autologous bispecific bcma/cd19-targeted car-t cells gc012f | cael-101 | |
|---|---|---|
| Developers | 0 | 2 |
| Clinical trials | 0 | 1 |
| FDA decisions | 0 | 0 |
| Generic name | Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | anselamimab |